FIELD: biochemistry.
SUBSTANCE: described is a group of inventions comprising a monoclonal antibody which binds to a human SEZ6 protein, a nucleic acid encoding a heavy chain of said antibody, a vector containing said nucleic acid, a nucleic acid coding a light chain of said antibody, a vector containing said nucleic acid, a host cell, an antibody-drug conjugate, a pharmaceutical composition for treating SEZ6-related disorder, use of said antibody or conjugate for preparing a drug for treating a malignant neoplasm, a method of treating a malignant growth, method for reducing the number of malignant cell-initiating cells in a patient, a kit for treating a malignant growth, a kit for reducing the number of cell malignant growths.
EFFECT: invention extends the range of products for binding with human SEZ6 protein.
56 cl, 52 dwg, 4 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
| DIAGNOSING AND TREATING MALIGNANT TUMOUR WITH USING ANTI-EREG ANTIBODY | 2007 |
|
RU2537245C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2633505C2 |
| ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES | 2007 |
|
RU2448980C2 |
